CBT-1® in Combination With Doxorubicin in Patients With Metastatic, Unresectable Sarcomas Who Previously Progressed on Doxorubicin
Palo Alto (17 mi)Age: 18+
Sex: Any
Travel: May be covered
Time Reimbursement: Varies
Trial Phase: Phase 1
Waitlist Available
Sponsor: CBA Research
No Placebo Group
Trial Summary
What is the purpose of this trial?This study evaluates the combination of CBT-1® and doxorubicin for the treatment of metastatic, unresectable sarcoma in patients who have progressed after treatment with 150mg/m2 or less of doxorubicin. Participants will receive CBT-1® on days 1-7 of each 21-day cycle, as well as doxorubicin on days 5 and 6.
Eligibility Criteria
Treatment Details
Find a clinic near you
Research locations nearbySelect from list below to view details:
Sarcoma Oncology Research CenterSanta Monica, CA
University of Pittsburgh Medical CenterPittsburgh, PA
Massachusetts General HospitalBoston, MA
Seattle Cancer Care AllianceSeattle, WA
More Trial Locations
Loading ...
Who is running the clinical trial?
CBA ResearchLead Sponsor